A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

PHASE1TerminatedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

December 31, 2012

Conditions
Multiple Sclerosis
Interventions
DRUG

ELND002

DRUG

Placebo

Trial Locations (20)

27607

Research Site, Raleigh

32960

Research Site, Vero Beach

33609

Research Site, Tampa

37920

Research Site, Knoxville

44685

Research Site, Uniontown

45219

Research Site, Cincinnati

48334

Research Site, Farmington Hills

55404

Research Site, Minneapolis

60062

Research Site, Northbrook

78258

Research Site, Cordova

Research Site, San Antonio

80045

Research Site, Aurora

84106

Research Site, Salt Lake City

87106

Research Site, Albuquerque

92663

Research Site, Newport Beach

93710

Research Site, Fresno

94705

Research Site, Berkeley

T2N 2T9

Research Site, Calgary

J4V 2J2

Research Site, Greenfield Park

H3A 2B4

Research Site, Montreal

Sponsors
All Listed Sponsors
lead

Elan Pharmaceuticals

INDUSTRY